Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells

被引:77
作者
Abu-Raya, S
Tabakman, R
Blaugrund, E
Trembovler, V
Lazarovici, P [1 ]
机构
[1] Hebrew Univ Jerusalem, Fac Med, Sch Pharm, Dept Pharmacol & Expt Therapeut, IL-91120 Jerusalem, Israel
[2] Teva Pharmaceut Ltd, Res & Dev Unit, Netanya, Israel
关键词
Parkinson's disease; rasagiline; selegiline; 1-R-aminoindan; L-methamphetamine; neurotoxicity; neuroprotection; oxygen-glucose deprivation;
D O I
10.1016/S0014-2999(01)01548-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Selegiline and rasagiline are selective and irreversible monoamine oxidase-B inhibitors that exert neuroprotective effects in various preclinical models. The aim of the present study was to examine the effect of selegiline and its major metabolite, L-methamphetamine in comparison to rasagiline and its major metabolite, 1-R-aminoindan on oxygen-glucose deprivation induced cell death in nerve growth factor (NGF)-differentiated pheochromocytoma (PC12) cells. Our results show that selegiline reduces oxygen-glucose deprivation induced cell death by 30%. When the cultures were treated with rasagiline at similar concentrations, cell death induced by oxygen-glucose deprivation was reduced by 45-55%. L-methamphetamine, a major selegiline metabolite, but not 1-R-aminoindan, the major rasagiline metabolite, enhanced oxygen-glucose deprivation-induced cell death by 70%. Under nonnoxic conditions, both metabolites lack neurotoxicity. Concomitant exposure of the cultures under oxygen-glucose deprivation, to a combination of either selegiline and L-methamphetamine or rasagiline and 1-R-aminoindan, indicated that L-methamphetamine, but not 1-R-aminoindan, blocked the neuroprotective effect of the parental drug. These results suggest there may be a neuroprotective advantage of rasagiline over selegiline. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:109 / 116
页数:8
相关论文
共 45 条
  • [1] Abu-Raya S, 2000, DRUG DEVELOP RES, V50, P285, DOI 10.1002/1098-2299(200007/08)50:3/4<285::AID-DDR11>3.0.CO
  • [2] 2-8
  • [3] Abu-Raya S, 1999, J NEUROSCI RES, V58, P456, DOI 10.1002/(SICI)1097-4547(19991101)58:3<456::AID-JNR12>3.0.CO
  • [4] 2-S
  • [5] ANSARI KS, 1993, J NEUROSCI, V13, P4042
  • [6] POTENTIATION OF ANTI AKINETIC EFFECT AFTER L-DOPA TREATMENT BY AN INHIBITOR OF MAO-B, DEPRENIL
    BIRKMAYER, W
    RIEDERER, P
    YOUDIM, MBH
    LINAUER, W
    [J]. JOURNAL OF NEURAL TRANSMISSION, 1975, 36 (3-4) : 303 - 326
  • [7] BONIECE IR, 1993, J NEUROSCI, V13, P4220
  • [8] Edsall LC, 1997, J NEUROSCI, V17, P6952
  • [9] EllrenKashi O, 1997, J NAT TOXINS, V6, P285
  • [10] ENGBERG G, 1991, J PHARMACOL EXP THER, V259, P841